Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Inclusion Criteria: * No prior sorafenib * Histologically or cytologically confirmed uterine carcinoma or carcinosarcoma: * Advanced or recurrent disease * Not amenable to curative surgery or radiotherapy * Measurable disease: * At least 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan * Tumor tissue block must be available * No known brain metastases * Performance status: * ECOG 0-2 OR * Karnofsky 60-100% * Hematopoietic: * Absolute neutrophil count \>= 1,500/mm3 * Platelet count \>= 100,000/mm3 * No bleeding diathesis * Hepatic: * Bilirubin normal * AST and ALT =\< 2.5 times upper limit of normal * Renal: * Creatinine =\< 1.5 mg/dL OR * Creatinine clearance \>= 60 mL/min * Cardiovascular: * No uncontrolled hypertension, defined by 1 of the following: * Blood pressure \> 150/100 mm Hg * Currently taking \> 1 antihypertensive agent * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other active malignancy * No history of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No swallowing dysfunction that would preclude study drug ingestion * No other uncontrolled illness * Prior biological response modifier therapy allowed * No prior antiangiogenesis therapy * No prior MAPK-signaling agents * No prior vascular endothelial growth factor receptor (VEGFR) inhibitors * No more than 1 prior chemotherapy regimen * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * Prior hormonal therapy allowed * Prior radiotherapy allowed provided the only site of measurable disease was not located within the radiation port OR disease has progressed since completion of therapy * Recovered from all prior therapy * Concurrent warfarin allowed provided all of the following are true: * Patient is therapeutic on a stable warfarin dose * INR target range =\< 3 * Patient is monitored with weekly INR testing * No active bleeding or pathological condition that carries a high bleeding risk * No concurrent combination antiretroviral therapy for HIV-positive patients * No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital) * No concurrent rifampin * No concurrent Hypericum perforatum (St. John's wort) * No other concurrent investigational agents * No other concurrent anticancer therapy * More than 4 weeks since prior radiotherapy